Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics Informs Crescendo Bio of Interest in Acquisition

NEW YORK (GenomeWeb News) – Myriad Genetics has informed Crescedo Bioscience of its “preliminary, non-binding interest” in acquiring the company, Myriad said in a regulatory document today.

The Salt Lake City firm informed Crescendo of its interest on Tuesday after Crescendo sent notice to Myriad on Nov. 14 that it had achieved a minimum revenue milestone, which gave Myriad the option to acquire Crescendo.

Myriad had made a $25 million investment in Crescendo in 2011 and as part of the investment Myriad received a three-year option to acquire Crescendo at its discretion. South San Francisco, Calif.-based Crescendo develops molecular diagnostic tests. Its lead product is the Vectra DA for rheumatoid arthritis.

If Myriad decides to purchase Crescendo, the purchase price will be “determined in accordance with the” merger agreement forged between the companies in 2011 concurrent with the $25 million investment, Myriad said in its document filed with the US Securities and Exchange Commission today. It added that if it buys Crescendo, it anticipates funding the deal with cash, cash equivalents, and marketable securities available on hand. As of Sept. 30 that amount was $515.6 million.

A deal would be completed during Myriad’s Fiscal Year 2014, ending June 30, it said.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.